Racial and ethnic equity in PAH clinical trials

Robyn Kalda
Dec 22, 2025
1 min read

Looking at the racial and ethnic breakdown of patients with PAH and patients who take part in clinical trials, the authors conclude that the goal of equitable representation has not yet been reached.

The article includes a useful table of potential barriers to inclusive clinical trials and potential solutions.

Read the Advances in Pulmonary Hypertension article

Recent Posts

In CTEPH, antioxidant enzyme PRDX2 reduces inflammation

A study found that chronic thromboembolic pulmonary hypertensio (CTEPH) patients had significantly more of an antioxidant enzyme (peroxiredoxin 2, or PRDX2) in their bloodstream compared to healthy pa

Early diagnosis and treatment of PAH improve survival

This study examined the causes of delayed diagnosis (diagnosis after approximately 22 months) of pulmonary arterial hypertension (PAH) and whether an earlier diagnosis (within six months) leads to bet

Blood test identified as a good biomarker for idiopathic PAH

A relatively simple, inexpensive, and minimally invasive test for idiopathic pulmonary arterial hypertension (IPAH) would aid in the diagnosis of this disease. This study found that levels of the NOTC

Comments